Sadie Stern, EVP Chief People and Culture Officer at DexCom Inc (NASDAQ:DXCM), filed a Form 4 on October 28, 2026, disclosing the sale of 2,565 shares of common stock on October 27, 2026, pursuant to a previously adopted 10b5-1 plan.

Key Highlights

  • Shares sold: 2,565 shares of DexCom common stock were disposed of on October 27, 2026.
  • Sale price: Shares were sold at $78.62 per share.
  • 10b5-1 plan: The sale was made under a plan adopted by Ms. Stern on May 28, 2026.
  • Remaining holdings: Following the transaction, Ms. Stern beneficially owned 120,913 shares directly.
  • Unvested RSUs: Included in the post-transaction total are 71,903 unvested restricted stock units across multiple grant dates.
  • RSU grant details: 39,019 RSUs granted March 8, 2026 vest through March 8, 2029; 19,948 and 5,699 RSUs granted March 8, 2025 vest through March 8, 2028 and March 8, 2027, respectively; 7,237 RSUs granted March 8, 2024 vest through March 8, 2027.

DexCom EVP Sadie Stern Executes Planned Share Sale Under 10b5-1 Program

According to the filing, Sadie Stern, who serves as Executive Vice President, Chief People and Culture Officer at DexCom Inc, sold 2,565 shares of the company's common stock on October 27, 2026, at a price of $78.62 per share. The transaction was coded as a sale ("S") in Table I of the Form 4 and is classified as a direct disposition.

The filing notes that on May 28, 2026, Ms. Stern adopted a Rule 10b5-1 plan, and that the shares reported were sold pursuant to that plan. The filing states the plan "allows the orderly disposition of shares owned by Ms. Stern." The transaction box indicating the sale was made pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) was checked on the form.

Following the reported transaction, Ms. Stern's direct beneficial ownership stood at 120,913 shares. The filing discloses that this total includes 71,903 unvested restricted stock units. Of those RSUs, 39,019 were granted on March 8, 2026 and vest through March 8, 2029; 19,948 were granted on March 8, 2025 and vest through March 8, 2028; 5,699 were granted on March 8, 2025 and vest through March 8, 2027; and 7,237 were granted on March 8, 2024 and vest through March 8, 2027. No derivative securities transactions were reported in Table II of the filing.

What Was Disclosed

DexCom EVP Sadie Stern filed a Form 4 reporting the sale of 2,565 shares of common stock at $78.62 on October 27, 2026, under a 10b5-1 plan adopted May 28, 2026, leaving her with 120,913 shares beneficially owned directly.